Retinoic acid receptor (RAR) and retinoid X receptor (RXR) agonists/antagonists
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XF Retinoids for cancer treatment
L01XF03 Bexarotene
D03106 Bexarotene (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Retinoids
Bexarotene
D03106 Bexarotene (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D03106 Bexarotene (JAN/USAN/INN)
Drug groups [BR:br08330]
Vitamin and mineral
DG01604 Retinol derivative
D03106 Bexarotene
Metabolizing enzyme inducer
DG02853 CYP3A/CYP3A4 inducer
D03106 Bexarotene
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Hepatocyte nuclear factor 4 like receptors
Retinoid X receptor (RXR)
NR2B (RXR)
D03106 Bexarotene (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03106
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03106
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03106
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03106
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03106